Jennifer Jao1, Brian Kirmse1, Chunli Yu1, Yunping Qiu1, Kathleen Powis1, Emmanuel Nshom1, Fanny Epie1, Pius Muffih Tih1, Rhoda S Sperling1, Elaine J Abrams1, Mitchell E Geffner1, Derek LeRoith1, Irwin J Kurland1. 1. Departments of Medicine (J.J.), Obstetrics, Gynecology, and Reproductive Science (J.J.), Genetics and Genomic Sciences (C.Y.), and Obstetrics, Gynecology, and Reproductive Science (R.S.S.), and Department of Medicine (D.L.), Division of Endocrinology, Icahn School of Medicine, Mt Sinai, New York, New York 10029; Department of Pediatrics (B.K.), Division of Genetics and Metabolism, Children's National Medical Center/George Washington University School of Medicine, Washington, DC 20037; Department of Medicine (Y.Q., I.J.K.), Division of Endocrinology, Albert Einstein College of Medicine, Bronx, New York 10461; Departments of Pediatrics and Internal Medicine (K.P.), Massachusetts General Hospital, Boston, Massachusetts 02114; Cameroon Baptist Convention Health Services (E.N., F.E., P.M.T.), Bamenda, Cameroon; ICAP (E.J.A.), Mailman School of Public Health and College of Physicians and Surgeons, Columbia University, New York, New York 10032; and The Saban Research Institute of Children's Hospital Los Angeles (M.E.G.), Keck School of Medicine of University of Southern California, Los Angeles, California 90033.
Abstract
CONTEXT: Intrauterine HIV/antiretroviral (ARV) and postnatal ARVs are known to perturb energy metabolism and could have permanent effects on future metabolic health. Such maladaptive effects could be mediated by changes in mitochondrial function and intermediary metabolism due to fetal and early-life ARV exposure in HIV/ARV-exposed uninfected (HEU) infants. OBJECTIVE: The objective of the study was to understand the relationship(s) between mitochondrial fuel use (assessed via acylcarnitines and branched chain amino acids) and preprandial insulin in infants exposed to in utero HIV/ARV plus postnatal zidovudine or nevirapine compared with HIV/ARV-unexposed uninfected (HUU) infants. DESIGN: This was a prospective cohort study with the following three groups: 1) intrauterine HIV/ARV/postnatal zidovudine-exposed (HEU-A), 2) intrauterine HIV/ARV/postnatal nevirapine-exposed (HEU-N), and 3) HUU infants. Principal component analysis and linear regression modeling were performed to assess the association between in utero HIV/ARV exposure and infant insulin. SETTING: The study was conducted at Cameroonian urban antenatal centers. PARTICIPANTS: HIV-infected and -uninfected pregnant woman/infant dyads participated in the study. MAIN OUTCOME: Preprandial insulin was the main outcome measured. RESULTS: Of 366 infants, 38 were HEU-A, 118 HEU-N. Forty intermediary metabolites were consolidated into seven principal components. In a multivariate analysis, both HEU-A (β = -.116, P= .012) and HEU-N (β = -.070, P= .022) demonstrated lower insulin compared with HUU infants. However, at high levels of plasma metabolites, HEU-A (β = .027, P= .050) exhibited higher insulin levels than HEU-N or HUU infants. A unique array of short-chain acylcarnitines (β = .044, P= .001) and branched-chain amino acids (β = .033, P= .012) was associated with insulin. CONCLUSION: HEU-A and HEU-N infants have lower preprandial insulin levels at 6 weeks of age and appear to use metabolic fuel substrates differently than HUU infants. Future studies are warranted to determine whether observed differences have lasting metabolic implications, such as later insulin resistance.
CONTEXT: Intrauterine HIV/antiretroviral (ARV) and postnatal ARVs are known to perturb energy metabolism and could have permanent effects on future metabolic health. Such maladaptive effects could be mediated by changes in mitochondrial function and intermediary metabolism due to fetal and early-life ARV exposure in HIV/ARV-exposed uninfected (HEU) infants. OBJECTIVE: The objective of the study was to understand the relationship(s) between mitochondrial fuel use (assessed via acylcarnitines and branched chain amino acids) and preprandial insulin in infants exposed to in utero HIV/ARV plus postnatalzidovudine or nevirapine compared with HIV/ARV-unexposed uninfected (HUU) infants. DESIGN: This was a prospective cohort study with the following three groups: 1) intrauterine HIV/ARV/postnatal zidovudine-exposed (HEU-A), 2) intrauterine HIV/ARV/postnatal nevirapine-exposed (HEU-N), and 3) HUU infants. Principal component analysis and linear regression modeling were performed to assess the association between in utero HIV/ARV exposure and infantinsulin. SETTING: The study was conducted at Cameroonian urban antenatal centers. PARTICIPANTS: HIV-infected and -uninfected pregnant woman/infant dyads participated in the study. MAIN OUTCOME: Preprandial insulin was the main outcome measured. RESULTS: Of 366 infants, 38 were HEU-A, 118 HEU-N. Forty intermediary metabolites were consolidated into seven principal components. In a multivariate analysis, both HEU-A (β = -.116, P= .012) and HEU-N (β = -.070, P= .022) demonstrated lower insulin compared with HUU infants. However, at high levels of plasma metabolites, HEU-A (β = .027, P= .050) exhibited higher insulin levels than HEU-N or HUU infants. A unique array of short-chain acylcarnitines (β = .044, P= .001) and branched-chain amino acids (β = .033, P= .012) was associated with insulin. CONCLUSION: HEU-A and HEU-N infants have lower preprandial insulin levels at 6 weeks of age and appear to use metabolic fuel substrates differently than HUU infants. Future studies are warranted to determine whether observed differences have lasting metabolic implications, such as later insulin resistance.
Authors: V Mericq; K K Ong; R Bazaes; V Peña; A Avila; T Salazar; N Soto; G Iñiguez; D B Dunger Journal: Diabetologia Date: 2005-11-08 Impact factor: 10.122
Authors: Christopher B Newgard; Jie An; James R Bain; Michael J Muehlbauer; Robert D Stevens; Lillian F Lien; Andrea M Haqq; Svati H Shah; Michelle Arlotto; Cris A Slentz; James Rochon; Dianne Gallup; Olga Ilkayeva; Brett R Wenner; William S Yancy; Howard Eisenson; Gerald Musante; Richard S Surwit; David S Millington; Mark D Butler; Laura P Svetkey Journal: Cell Metab Date: 2009-04 Impact factor: 27.287
Authors: Irwin J Kurland; Domenico Accili; Charles Burant; Steven M Fischer; Barbara B Kahn; Christopher B Newgard; Suma Ramagiri; Gabriele V Ronnett; John A Ryals; Mark Sanders; Joe Shambaugh; John Shockcor; Steven S Gross Journal: Ann N Y Acad Sci Date: 2013-05-09 Impact factor: 5.691
Authors: Jennifer Jao; Denise L Jacobson; Wendy Yu; William Borkowsky; Mitchell E Geffner; Elizabeth J McFarland; Kunjal Patel; Paige L Williams; Tracie Miller Journal: J Acquir Immune Defic Syndr Date: 2019-07-01 Impact factor: 3.731
Authors: Jennifer Jao; Kathleen M Powis; Brian Kirmse; Chunli Yu; Fanny Epie; Emmanuel Nshom; Elaine J Abrams; Rhoda S Sperling; Derek Leroith; Mitchell E Geffner; Irwin J Kurland; Hélène C F Côté Journal: AIDS Date: 2017-11-28 Impact factor: 4.177
Authors: Robert Klitzman; Claude A Mellins; Morgan M Philbin; Elaine J Abrams; Robert H Remien Journal: Am J Public Health Date: 2016-06-16 Impact factor: 9.308
Authors: Lindsay T Fourman; Chelsea S Pan; Isabel Zheng; Marisa E Gerard; Asia Sheehab; Hang Lee; Takara L Stanley; Steven K Grinspoon Journal: J Acquir Immune Defic Syndr Date: 2020-02-01 Impact factor: 3.771
Authors: Charlotte E Lane; Elizabeth M Widen; Shalean M Collins; Sera L Young Journal: J Acquir Immune Defic Syndr Date: 2020-10-01 Impact factor: 3.771